| __timestamp | Bausch Health Companies Inc. | Mesoblast Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 246000000 | 55305000 |
| Thursday, January 1, 2015 | 582800000 | 77593000 |
| Friday, January 1, 2016 | 455000000 | 50013000 |
| Sunday, January 1, 2017 | 366000000 | 58914000 |
| Monday, January 1, 2018 | 414000000 | 65927000 |
| Tuesday, January 1, 2019 | 471000000 | 59815000 |
| Wednesday, January 1, 2020 | 452000000 | 56188000 |
| Friday, January 1, 2021 | 465000000 | 53012000 |
| Saturday, January 1, 2022 | 529000000 | 32815000 |
| Sunday, January 1, 2023 | 604000000 | 27189000 |
| Monday, January 1, 2024 | 25353000 |
Unleashing the power of data
In the ever-evolving landscape of pharmaceuticals, research and development (R&D) expenses are a critical indicator of a company's commitment to innovation. Over the past decade, Bausch Health Companies Inc. and Mesoblast Limited have demonstrated contrasting trajectories in their R&D investments.
Bausch Health has consistently increased its R&D spending, peaking in 2023 with a 146% rise from 2014. This upward trend underscores their strategic focus on expanding their product pipeline. In contrast, Mesoblast Limited's R&D expenses have seen a gradual decline, dropping by approximately 54% from 2014 to 2023. This reduction may reflect a shift in strategic priorities or financial constraints.
These trends highlight the dynamic nature of the pharmaceutical industry, where strategic investments in R&D can significantly impact a company's competitive edge and future growth prospects.
Research and Development Expenses Breakdown: Novo Nordisk A/S vs Mesoblast Limited
Research and Development: Comparing Key Metrics for argenx SE and Bausch Health Companies Inc.
Who Prioritizes Innovation? R&D Spending Compared for United Therapeutics Corporation and Bausch Health Companies Inc.
Intra-Cellular Therapies, Inc. or Mesoblast Limited: Who Invests More in Innovation?
Comparing Innovation Spending: Ascendis Pharma A/S and Mesoblast Limited
Amneal Pharmaceuticals, Inc. or Mesoblast Limited: Who Invests More in Innovation?
Analyzing R&D Budgets: Veracyte, Inc. vs Bausch Health Companies Inc.
R&D Insights: How ACADIA Pharmaceuticals Inc. and Bausch Health Companies Inc. Allocate Funds
Comparing Cost of Revenue Efficiency: Bausch Health Companies Inc. vs Mesoblast Limited
Analyzing R&D Budgets: Bausch Health Companies Inc. vs Ligand Pharmaceuticals Incorporated
R&D Spending Showdown: Mesoblast Limited vs Galapagos NV
R&D Insights: How Mesoblast Limited and Celldex Therapeutics, Inc. Allocate Funds